$SNDY subbie on watch. Nice news: Solos Endoscopy
Post# of 94279
(Total Views: 135)
Posted On: 01/06/2017 10:01:53 AM
$SNDY subbie on watch. Nice news: Solos Endoscopy Sales Increase by 20% for First Quarter 2016
BOSTON, MA--(Marketwired - May 12, 2016) - Solos Endoscopy, Inc. ( OTC PINK : SNDY ) is pleased to announce that the Company expects to show a sales increase of more than 20% as compared to the fourth quarter of last year when it posts its first quarter financials for period ended March 31, 2016.
Solos Endoscopy's sales increased from $65,917.66 for the quarter ending December 31, 2015 to $79,622.89 for the first quarter of this year. This was accomplished without any increase in its current pricing structure or negative impact on its margins. Solos management expects the positive trend to continue as the demand for endoscopic instruments has been increasing worldwide.
The industry has developed several new modifications to its endoscopic instrument lines to accommodate the continual advances in laparoscopic surgical procedures. The significant advances over the past several years have led to a number of advantages to the patient with laparoscopic surgery versus an open procedure (laparotomy). The demand for endoscope services is increasing due to an increase in the aging and chronically ill population coupled with the expansion of medical procedures utilizing minimally invasive techniques. Advancements in endoscopic technologies and inclusion of various types of scopes, light sources, video cameras, real-time conversion of data into three-dimensional images are also driving this market.
Solos Endoscopy expects to post its first quarter financials on the OTC Markets website within the next two weeks. The Company will also be releasing it's "President's Report" for distribution to its shareholders in the next thirty days.
"We are very pleased with this positive development and, coupled with an increase in demand for our MammoView product line, we look forward to a bright future," stated Bob Segersten, President of Solos Endoscopy, Inc.
Read Full: http://finance.yahoo.com/news/solos-endoscopy...25940.html
BOSTON, MA--(Marketwired - May 12, 2016) - Solos Endoscopy, Inc. ( OTC PINK : SNDY ) is pleased to announce that the Company expects to show a sales increase of more than 20% as compared to the fourth quarter of last year when it posts its first quarter financials for period ended March 31, 2016.
Solos Endoscopy's sales increased from $65,917.66 for the quarter ending December 31, 2015 to $79,622.89 for the first quarter of this year. This was accomplished without any increase in its current pricing structure or negative impact on its margins. Solos management expects the positive trend to continue as the demand for endoscopic instruments has been increasing worldwide.
The industry has developed several new modifications to its endoscopic instrument lines to accommodate the continual advances in laparoscopic surgical procedures. The significant advances over the past several years have led to a number of advantages to the patient with laparoscopic surgery versus an open procedure (laparotomy). The demand for endoscope services is increasing due to an increase in the aging and chronically ill population coupled with the expansion of medical procedures utilizing minimally invasive techniques. Advancements in endoscopic technologies and inclusion of various types of scopes, light sources, video cameras, real-time conversion of data into three-dimensional images are also driving this market.
Solos Endoscopy expects to post its first quarter financials on the OTC Markets website within the next two weeks. The Company will also be releasing it's "President's Report" for distribution to its shareholders in the next thirty days.
"We are very pleased with this positive development and, coupled with an increase in demand for our MammoView product line, we look forward to a bright future," stated Bob Segersten, President of Solos Endoscopy, Inc.
Read Full: http://finance.yahoo.com/news/solos-endoscopy...25940.html
(0)
(0)